Study of the Safety of KSP Heptapeptide (KSP-910638G)

Completed · Phase 1

Conditions studied: Healthy Adults

In brief

The purpose of this study is to evaluate the safety of orally administered KSP-910638G, a topically administered li-cor IRDye800CW labeled heptapeptide specific for human epithelial growth factor receptor 2 (HER2).

Key facts

Study ID

NCT03161418

Run by

University of Michigan

People needed

26

Starts

2017-06-21

Expected to finish

2017-09-20

Last updated by the study team

2017-12-05

Who can join

Age: 25 and older, up to 100. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Not pregnant (willing to have pregnancy test if applicable)
• No recent illness (infection, URI, virus or flu) within 2 weeks,
• Stable health status (i.e. no medication changes within 2 months, no recent surgery, etc. per PI)
• Willing and able to sign informed consent
• Willing and able to drink the peptide and a tap water chaser
• Willing and able to get baseline and 24-48 hours post ingestion labs

You may not qualify if…

• Known allergy to li-cor IRDye800CW, a near infrared fluorosphore or derivatives
• Subjects on active chemotherapy or radiation therapy
• Diabetics on insulin/hypoglycemic (due to fasting requirements)

Where it is running

• University of Michigan — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.